Abstract： Objective： To observe the clinical efficacy of Qingqi Huatan Sanjie Decoction in the treatment of intermediate-risk pulmonary nodules of lung stagnation and phlegm stasis type. Methods：A total of 104 patients with intermediate-risk pulmonary nodules of lung stagnation and phlegm stasis type admitted to Quzhou Hospital of Traditional Chinese Medicine from January to September 2025 were enrolled. They were randomly divided into the observation group and the control group using the random number table method， with 52 cases in each group. The observation group received Qingqi Huatan Sanjie Decoction， while the control group received no intervention. After three months， the two groups were compared in terms of clinical efficacy， changes in traditional Chinese medicine syndrome score，maximum nodule diameter and area，levels of inflammatory factors [tumor necrosis factor-α（ TNF-α）， interleukin-6 （IL-6），interleukin-17A （IL-17A）]，and T lymphocyte subsets. Results：After treatment，the total effective rate was 44.23% （23/52） in the observation group and 9.62% （5/52） in the control group，and the difference between the two groups was statistically significant （P＜0.05）. After treatment， the traditional Chinese medicine syndrome score in the observation group decreased compared with that before treatment，and it was also lower than that in the control group （P＜0.05）；whereas no statistically significant difference was found in the control group before and after treatment （P＞0.05）. After treatment，the maximum nodule diameter and maximum nodule area in the observation group were reduced compared with those before treatment and with the control group （P＜0.05）； no significant differences were observed in the control group before and after treatment （P＞0.05）. After treatment， the levels of TNF-α，IL-6，and IL-17A in the observation group decreased compared with those before treatment，and the levels were also lower than those in the control group （P＜0.05）；no significant differences were found in the control group before and after treatment （P＞0.05）. After treatment， CD4+ levels and CD4+/CD8+ ratio in the observation group increased，and CD8+ levels decreased，compared with those before treatment and with the control group （P＜0.05）； no significant changes in levels of CD4+ and CD8+，or CD4+/CD8+ ratio were observed in the control group before and after treatment （P＞0.05）. During the study， no obvious adverse reactions occurred in either group. Conclusion： Qingqi Huatan Sanjie Decoction is effective in the treatment of intermediate-risk pulmonary nodules of lung stagnation and phlegm stasis type. It can improve traditional Chinese medicine syndrome manifestations， reduce nodule size， alleviate systemic inflammatory response，enhance immune functory，and has a good safety profile.